Yale’s Department of Surgery is a premier center for adult and pediatric surgical treatment, providing comprehensive care for a full range of conditions and diseases. To ensure that our patients experience shorter hospital stays and less postoperative discomfort, we employ the latest technologies and surgical techniques, and perform minimally invasive surgery whenever possible. Our renowned surgeons and faculty continue to push the frontiers of surgical science through innovative treatment and leading-edge research, with the ability to offer treatment options that can be difficult to find elsewhere. More state-of-the-art surgical suites at Yale New Haven Hospital than in any other hospital in the region Collaboration with the Yale Department of Biomedical Engineering and with industry to develop 3-D bioprinting for the regeneration, repair, and replacement of human tissue and vessels Nationally recognized Center of Excellence and designated training center for transcatheter aortic valve replacement (TAVR) Yale’s Endocrine Neoplasia Laboratory is an internationally renowned multidisciplinary research group in which surgeons work with endocrine geneticists to decipher the molecular genetics of endocrine tumor disease First program in Connecticut to offer three different minimally invasive bariatric surgical techniques: Roux-en-Y gastric bypass, LAP-Band® surgery, and laparoscopic sleeve gastrectomy

Covering every aspect of health care for adults, Internal Medicine is the largest department in the Yale School of Medicine, and the largest clinical service at Yale New Haven Hospital. We provide comprehensive and specialized services in all areas in a variety of outpatient settings as well as the Veterans Affairs (VA) Connecticut Health Care System campus in West Haven. Our culture of collaboration and research gives patients access to expert opinions from nearly 1,000 doctors, as well as opportunities to get tomorrow’s health care today through more than 100 clinical trials. Most importantly, we attend to our diverse community of patients with compassionate, thorough care. Specialized care is offered in the following areas: Allergy & clinical immunology Cardiovascular medicine Digestive diseases Endocrinology General internal medicine Geriatrics Hematology Infectious diseases Medical oncology Occupational health & environmental medicine Nephrology Pulmonology, critical care & sleep medicine Rheumatology International reputation for work in understanding function, independence, and quality of life in older persons Key research breakthroughs of the past decade that include the development of a protective Lyme bacillus disease vaccine, exploration of the underlying causes of allergic disease, and the discovery of novel inherited immunological diseases Largest interventional cardiology program in Connecticut Major referral center for patients with type 1 and type 2 diabetes, as well as other metabolic conditions Nationally ranked program in kidney diseases and the largest kidney transplant program in New England, with multidisciplinary care clinics One of the largest peripheral vascular programs in the country, with leadership and participation in multiple new percutaneous device trials Once of only a few motility centers in Connecticut to provide all motility procedures and services Unique medical forensic exams for individuals with claims of torture who are seeking asylum in the U.S.

The Hepatic Arterial Infusion (HAI) Program at Smilow Cancer Hospital consists of a multidisciplinary team of nationally recognized physicians who are experts in diagnosing, treating, and providing care for patients with colorectal cancer , cholangiocarcinoma (bile duct cancer), and liver cancer . HAI is a specialized and targeted approach to deliver chemotherapy directly to the liver, primarily used in the treatment of advanced liver metastases from colorectal cancer, in addition to intrahepatic cholangiocarcinoma. Traditional systemic chemotherapy and immunotherapy may not provide enough concentration of the drug within the liver while minimizing exposure to the rest of the body. The procedure involves implanting an HAI pump (the size of a hockey puck) under the skin between the patient’s ribs and pelvis. The pump contains a catheter connected to the hepatic artery, the main blood vessel that supplies the liver with blood. This catheter allows for the direct infusion of chemotherapy drugs into the arterial blood supply of the liver. By administering chemotherapy directly to the affected organ, HAI will maximize the concentration of the drugs in the tumor tissue while minimizing their dilution and distribution throughout the rest of the body. The procedure typically lasts about three hours, and the pump will remain in the patient for several years. Patients will need to visit their doctor every two weeks to have the pump filled with chemotherapy, which takes approximately 10 minutes. Generally, patients will not notice the presence of the HAI pump, but should avoid rigorous physical activity, contact sports, or exposure to extreme heat, which could allow too much chemotherapy to enter the liver. The benefits of HAI include: Fewer side effects: The HAI pump allows for chemotherapy to be released directly into the liver, which is significantly more effective than traditional chemotherapy treatment. This chemotherapy remains in the liver and does not circulate throughout the patient’s body, thus limiting the side effects of treatment. Better outcomes: Chemotherapy is released into the liver continuously and is highly effective in reducing the recurrence of, controlling, or shrinking cancerous tumors in the liver. While uncommon, the HAI procedure does present a risk of complications, including infection, bleeding around the pump, or damage to the hepatic artery. Patients can be assured that our clinicians have extensive processes and procedures in place to ensure that risks are reduced before, during, and after surgery. Despite its benefits, HAI is not suitable for all patients. It is typically considered when the cancer is confined to the liver and systemic disease is limited. Patient selection is crucial, and our multidisciplinary team of medical oncologists, surgical oncologists, and interventional radiologists collaborate to determine the most appropriate candidates for this treatment.